These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 12521386)

  • 21. Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients.
    Herrington JD; Dinh BC
    J Oncol Pharm Pract; 2015 Apr; 21(2):111-7. PubMed ID: 24549060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single 6-mg dose of rasburicase: The experience in a large academic medical center.
    Nauffal M; Redd R; Ni J; Stone RM; DeAngelo DJ; McDonnell AM
    J Oncol Pharm Pract; 2019 Sep; 25(6):1349-1356. PubMed ID: 30111244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rasburicase for the treatment of tumor lysis in hematological malignancies.
    Malaguarnera G; Giordano M; Malaguarnera M
    Expert Rev Hematol; 2012 Feb; 5(1):27-38. PubMed ID: 22272702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia.
    Martens KL; Khalighi PR; Li S; White AA; Silgard E; Frieze D; Estey E; Garcia DA; Hingorani S; Li A
    Leuk Res; 2020 Feb; 89():106298. PubMed ID: 31945598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies.
    Ribeiro RC; Pui CH
    Clin Lymphoma; 2003 Mar; 3(4):225-32. PubMed ID: 12672271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind-randomized study.
    De Angelis S; Noce A; Di Renzo L; Cianci R; Naticchia A; Giarrizzo GF; Giordano F; Tozzo C; Splendiani G; De Lorenzo A
    Eur Rev Med Pharmacol Sci; 2007; 11(3):179-84. PubMed ID: 17970234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
    Kikuchi A; Kigasawa H; Tsurusawa M; Kawa K; Kikuta A; Tsuchida M; Nagatoshi Y; Asami K; Horibe K; Makimoto A; Tsukimoto I
    Int J Hematol; 2009 Nov; 90(4):492-500. PubMed ID: 19701676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome.
    Jeha S; Pui CH
    Contrib Nephrol; 2005; 147():69-79. PubMed ID: 15604607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis.
    Lopez-Olivo MA; Pratt G; Palla SL; Salahudeen A
    Am J Kidney Dis; 2013 Sep; 62(3):481-92. PubMed ID: 23684124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies.
    Yaman S; Başcı S; Turan G; Ulu BU; Yiğenoğlu TN; Dal MS; Kızıl Çakar M; Altuntaş F
    Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):e71-e76. PubMed ID: 34565690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Rasburicase (Fasturtec)].
    Vogt B; Gugger M; Frey FJ
    Ther Umsch; 2004 Sep; 61(9):579-82. PubMed ID: 15493120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
    Feng X; Dong K; Pham D; Pence S; Inciardi J; Bhutada NS
    J Clin Pharm Ther; 2013 Aug; 38(4):301-8. PubMed ID: 23550846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer.
    Cheuk DK; Chiang AK; Chan GC; Ha SY
    Cochrane Database Syst Rev; 2010 Jun; (6):CD006945. PubMed ID: 20556770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of impending tumor lysis with single-dose rasburicase.
    Lee AC; Li CH; So KT; Chan R
    Ann Pharmacother; 2003 Nov; 37(11):1614-7. PubMed ID: 14565793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.
    McBride A; Lathon SC; Boehmer L; Augustin KM; Butler SK; Westervelt P
    Pharmacotherapy; 2013 Mar; 33(3):295-303. PubMed ID: 23456733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of recombinant urate oxidase (rasburicase) for treatment and prophylaxis of hyperuricemia in children undergoing chemotherapy.
    Pession A; Barbieri E; Santoro N; Paolucci P; Porta F; Locatelli F
    Haematologica; 2005 Jan; 90(1):141-2. PubMed ID: 15642687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy.
    Hutcherson DA; Gammon DC; Bhatt MS; Faneuf M
    Pharmacotherapy; 2006 Feb; 26(2):242-7. PubMed ID: 16466328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rasburicase versus intravenous allopurinol for non-malignancy-associated acute hyperuricemia in paediatric cardiology patients.
    Moss JD; Wu M; Axelrod DM; Kwiatkowski DM
    Cardiol Young; 2019 Sep; 29(9):1160-1164. PubMed ID: 31451121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies.
    Wang LY; Shih LY; Chang H; Jou ST; Lin KH; Yeh TC; Lin SF; Liang DC
    Acta Haematol; 2006; 115(1-2):35-8. PubMed ID: 16424647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of single-dose rasburicase in an obese female.
    Arnold TM; Reuter JP; Delman BS; Shanholtz CB
    Ann Pharmacother; 2004 Sep; 38(9):1428-31. PubMed ID: 15292497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.